We serve Chemical Name:H-TRP-NH2 HCL CAS:5022-65-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:H-TRP-NH2 HCL
CAS.NO:5022-65-1
Synonyms:1H-Indole-3-propanamide, α-amino-, ethanedioate (1:1);(2S)-2-amino-3-(1H-indol-3-yl)propanamide,hydrochloride;L-TryptophanaMide Hydrochloride;L-Tryptophane Amide Hydrochloride;Tryptophanamide ethanedioate (1:1);EINECS 225-708-9;MFCD00054315;H-Trp-NH2·HCl;H-TRP-NH2 HCL
Molecular Formula:C13H15N3O5
Molecular Weight:293.275
HS Code:2933990090
Physical and Chemical Properties:
Melting point:250ºC
Boiling point:498.7ºC at 760mmHg
Density:N/A
Index of Refraction:25 ° (C=1, H2O)
PSA:159.50000
Exact Mass:293.101166
LogP:1.07920
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 1H-Indole-3-propanamide, α-amino-, ethanedioate (1:1) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,H-TRP-NH2 HCL physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-Indole-3-propanamide, α-amino-, ethanedioate (1:1) Use and application,EINECS 225-708-9 technical grade,usp/ep/jp grade.
Related News: In that group, the vaccine slowed brain decline by around 30% in two different clinical and functional tests, Novak said. H-TRP-NH2 HCL manufacturer It has reserves in the direction of APIs and intermediates for lowering blood lipids, lowering blood sugar and anticoagulation. H-TRP-NH2 HCL supplier From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. H-TRP-NH2 HCL vendor From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. H-TRP-NH2 HCL factory From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said.
